12 December 2019Press ReleaseCergentis launches TLA technology for complete cancer gene mutation sequencingUTRECHT, THE NETHERLANDS - 07:00 CET, December 12, 2019 - Cergentis, a genomics company that develops and commercialises kits and services based on its propriet...Read more 1 November 2019News UpdateCergentis appoints new CFOIt is a true pleasure to announce that Jean-Marc Roelandt has joined Cergentis as Chief Financial Officer. Jean-Marc is a senior level executive with more than ...Read more 16 September 2019Press ReleaseCergentis appoints new boardUtrecht, The Netherlands - September 16, 2019. Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targete...Read more 11 September 2019News UpdateCergentis on track with product development of TLA-based targeted complete next generation sequencing on FFPE samples for cancer diagnosticsBy combining proximity ligation with improved targeting strategies, we are able to sequence genes of interest completely, over a large width of 100’s of kilobas...Read more 8 September 2019PublicationsPacBio & Cergentis: TLA and Long-Read SequencingPacific Biosciences and Cergentis have presented the combination of TLA and the Pacific Biosciences SMRT sequencing technology...Read more 31 August 2019News UpdateNew appnote releasedCergentis released a new application note: "Complete locus sequencing and quality control of targeted genome editing". ...Read more 1 August 2019BlogNew laboratory robotsOur new laboratory robots have arrived at our facility. ...Read more 9 April 2019News UpdateCergentis releases two new application notes: improving QC in cell & gene therapy manufacturing with TLAOur Targeted Locus Amplification (TLA) technology has unique advantages in the quality control of transgenic and genetically engineered samples. TLA can assess ...Read more 8 April 2019BlogOur attendance at BPI 2019; a short reviewFrom April 2 to 5, Cergentis attended the Bioprocessing International (BPI) Europe conference in Vienna, Austria....Read more 5 March 2019News UpdateCergentis’ TLA technology and Genedata software: efficient in-house data analysis for CHO cell line developmentTLA is used in multiple stages in CHO cell line development, e.g. early stage clone selection, and enables the assessment of genetic stability of Master Cell Ba...Read more
© 2012-2020 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.